Ruqin Chen is an Oncology physician affiliated with Mayo Clinic in Florida. OpenAlex indexes 38 publications with 1,126 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4500 San Pablo Rd S
Jacksonville, FL 322241865
Telephone
904-953-2000Provider last certified this registry record 16 Dec 2021.
Clinical trials
- Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Sponsor: Mayo Clinic
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Immunocore LimitedProgram year202513 payments
- Genmab U.S., Inc.Program year20241 payment
- Merck Sharp & Dohme LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Patient experience and quality of life in a decentralized cancer care model for advanced prostate cancer.
Journal of Clinical Oncology
2026 - National patterns of overtreatment in low-risk and undertreatment in high-risk prostate cancer and associated survival impact.
Journal of Clinical Oncology
2026 - NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma
European Journal of Cancer
2025 - NeoACTIVATE arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable stage III melanoma.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Keith Oken, MD
Mayo Clinic in Florida
Robert Smallridge, MD
Mayo Clinic in Florida
Edith A. Perez
Mayo Clinic in Florida
Thomas Gonwa, MD
Mayo Clinic in Florida
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”